Acceptance No. | Drug Name | Active Ingredient | Dosage Form | Classification | Submission | Acceptance Date | Manufacturers | Manufacturers | Review Status | Status Date | View |
---|---|---|---|---|---|---|---|---|---|---|---|
JXSL1200016 | AVE0005注射液 | aflibercept | Injection | Biological Products | Import Drug Application | 2012-03-28 | sanofi-aventis groupe | Sanofi-Aventis Groupe | Certificate Issued | 2014-08-13 | view |
JXSL1200015 | AVE0005注射液 | aflibercept | Injection | Biological Products | Import Drug Application | 2012-03-31 | sanofi-aventis groupe | Sanofi-Aventis Groupe | Certificate Issued | 2014-08-13 | view |
JYHB1301024 | 注射用拉布立海 | rasburicase | Lyophilized | Chemical Drugs | Supplementary Application | 2013-09-26 | Sanofi-aventis groupe | Sanofi-Aventis Groupe;Sanofi-Aventis SpA | Approval Completed-Pending Certificated | 2014-09-25 | view |
JXSS1900067 | Dupilumab注射液 | dupilumab | Injection | Biological Products | Import Drug Application | 2019-12-25 | Sanofi-aventis groupe | Sanofi-Aventis Groupe;Sanofi Winthrop Industrie | Certificate Issued | 2020-06-22 | view |
JYSB2000388 | 度普利尤单抗注射液 | dupilumab | Injection | Biological Products(3.1) | Supplementary Application | 2020-08-21 | Sanofi-aventis groupe | Sanofi-Aventis Groupe;Sanofi Winthrop Industrie | Filed | 2020-09-02 | view |